Role of N6-methyladenosine Methylation in Glioma: Recent Insights and Future Directions

Overview

Journal Cell Mol Biol Lett

Publisher Biomed Central

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2023 Dec 10

PMID 38072944

Authors

Chunlin Li

Bowen Li

Hui Wang

Linglong Qu

Hui Liu

Chao Weng

Jinming Han

Yuan Li

Affiliations

Soon will be listed here.

Abstract

Glioma is the most pervasive intracranial tumor in the central nervous system (CNS), with glioblastoma (GBM) being the most malignant type having a highly heterogeneous cancer cell population. There is a significantly high mortality rate in GBM patients. Molecular biomarkers related to GBM malignancy may have prognostic values in predicting survival outcomes and therapeutic responses, especially in patients with high-grade gliomas. In particular, N6-methyladenine (m6A) mRNA modification is the most abundant form of post-transcriptional RNA modification in mammals and is involved in regulating mRNA translation and degradation. Cumulative findings indicate that m6A methylation plays a crucial part in neurogenesis and glioma pathogenesis. In this review, we summarize recent advances regarding the functional significance of m6A modification and its regulatory factors in glioma occurrence and progression. Significant advancement of m6A methylation-associated regulators as potential therapeutic targets is also discussed.

Citing Articles

Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma.

Lu Y, Wang Z, Zhang D, Luo N, Yang H, Chen D Cell Mol Neurobiol. 2024; 45(1):6.

PMID: 39692767 PMC: 11655607. DOI: 10.1007/s10571-024-01515-z.

Detecting the Tumor Prognostic Factors From the YTH Domain Family Through Integrative Pan-Cancer Analysis.

Zhu C, Yang Q, Mu X, Zhai Y, Zhao W, Yin Z Cancer Inform. 2024; 23:11769351241300030.

PMID: 39553336 PMC: 11569503. DOI: 10.1177/11769351241300030.

Intracellular C5aR1 inhibits ferroptosis in glioblastoma through METTL3-dependent m6A methylation of GPX4.

Meng X, Wang Z, Yang Q, Liu Y, Gao Y, Chen H Cell Death Dis. 2024; 15(10):729.

PMID: 39368999 PMC: 11455874. DOI: 10.1038/s41419-024-06963-5.

N6-methyladenosine modification of KLF2 may contribute to endothelial-to-mesenchymal transition in pulmonary hypertension.

Kang K, Xiang J, Zhang X, Xie Y, Zhou M, Zeng L Cell Mol Biol Lett. 2024; 29(1):69.

PMID: 38741032 PMC: 11089701. DOI: 10.1186/s11658-024-00590-w.

Decoding epitranscriptomic regulation of viral infection: mapping of RNA N-methyladenosine by advanced sequencing technologies.

Fan X, Zhang Y, Guo R, Yue K, Smagghe G, Lu Y Cell Mol Biol Lett. 2024; 29(1):42.

PMID: 38539075 PMC: 10967200. DOI: 10.1186/s11658-024-00564-y.

References

LaPointe S, Perry A, Butowski N . Primary brain tumours in adults. Lancet. 2018; 392(10145):432-446. DOI: 10.1016/S0140-6736(18)30990-5. View

Yin D, Kong C, Chen M . Effect of hnRNPA2/B1 on the proliferation and apoptosis of glioma U251 cells via the regulation of AKT and STAT3 pathways. Biosci Rep. 2020; 40(7). PMC: 7350891. DOI: 10.1042/BSR20190318. View

Xi Z, Wang P, Xue Y, Shang C, Liu X, Ma J . Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget. 2017; 8(15):24949-24963. PMC: 5421901. DOI: 10.18632/oncotarget.15327. View

Dai X, Shi L, Li Z, Yang H, Wei J, Ding Q . Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers. Front Oncol. 2021; 11:635329. PMC: 8076607. DOI: 10.3389/fonc.2021.635329. View

Linder B, Grozhik A, Olarerin-George A, Meydan C, Mason C, Jaffrey S . Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015; 12(8):767-72. PMC: 4487409. DOI: 10.1038/nmeth.3453. View

Pan Z, Zhao R, Li B, Qi Y, Qiu W, Guo Q . EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3. Mol Cancer. 2022; 21(1):16. PMC: 8759291. DOI: 10.1186/s12943-021-01485-6. View

Zhang Z, Wang M, Xie D, Huang Z, Zhang L, Yang Y . METTL3-mediated N-methyladenosine mRNA modification enhances long-term memory consolidation. Cell Res. 2018; 28(11):1050-1061. PMC: 6218447. DOI: 10.1038/s41422-018-0092-9. View

Galardi S, Michienzi A, Ciafre S . Insights into the Regulatory Role of mA Epitranscriptome in Glioblastoma. Int J Mol Sci. 2020; 21(8). PMC: 7215676. DOI: 10.3390/ijms21082816. View

Wang Y, Li Y, Yue M, Wang J, Kumar S, Wechsler-Reya R . N-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications. Nat Neurosci. 2018; 21(2):195-206. PMC: 6317335. DOI: 10.1038/s41593-017-0057-1. View

10.

Zhu W, Wang J, Xu Z, Cao M, Hu Q, Pan C . Detection of N6‑methyladenosine modification residues (Review). Int J Mol Med. 2019; 43(6):2267-2278. PMC: 6488182. DOI: 10.3892/ijmm.2019.4169. View

11.

Wang P, Doxtader K, Nam Y . Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. Mol Cell. 2016; 63(2):306-317. PMC: 4958592. DOI: 10.1016/j.molcel.2016.05.041. View

12.

Chen J, Zhang Y, Huang C, Shen H, Sun B, Cheng X . mA Regulates Neurogenesis and Neuronal Development by Modulating Histone Methyltransferase Ezh2. Genomics Proteomics Bioinformatics. 2019; 17(2):154-168. PMC: 6620265. DOI: 10.1016/j.gpb.2018.12.007. View

13.

Dixit D, Prager B, Gimple R, Poh H, Wang Y, Wu Q . The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2020; 11(2):480-499. PMC: 8110214. DOI: 10.1158/2159-8290.CD-20-0331. View

14.

Huang W, Chen T, Fang K, Zeng Z, Ye H, Chen Y . N6-methyladenosine methyltransferases: functions, regulation, and clinical potential. J Hematol Oncol. 2021; 14(1):117. PMC: 8313886. DOI: 10.1186/s13045-021-01129-8. View

15.

Chai R, Wu F, Wang Q, Zhang S, Zhang K, Liu Y . mA RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. Aging (Albany NY). 2019; 11(4):1204-1225. PMC: 6402513. DOI: 10.18632/aging.101829. View

16.

Piperi C, Markouli M, Gargalionis A, Papavassiliou K, Papavassiliou A . Deciphering glioma epitranscriptome: focus on RNA modifications. Oncogene. 2023; 42(28):2197-2206. DOI: 10.1038/s41388-023-02746-y. View

17.

Jin D, Guo J, Wu Y, Yang L, Wang X, Du J . mA demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. Mol Cancer. 2020; 19(1):40. PMC: 7045432. DOI: 10.1186/s12943-020-01161-1. View

18.

Yoon K, Vissers C, Ming G, Song H . Epigenetics and epitranscriptomics in temporal patterning of cortical neural progenitor competence. J Cell Biol. 2018; 217(6):1901-1914. PMC: 5987727. DOI: 10.1083/jcb.201802117. View

19.

Jin P, Huang Y, Zhu P, Zou Y, Shao T, Wang O . CircRNA circHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling. Biochem Biophys Res Commun. 2018; 503(3):1570-1574. DOI: 10.1016/j.bbrc.2018.07.081. View

20.

Visvanathan A, Patil V, Arora A, Hegde A, Arivazhagan A, Santosh V . Essential role of METTL3-mediated mA modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2017; 37(4):522-533. DOI: 10.1038/onc.2017.351. View